[ad_1]
Moderna is up to date. And one more step towards Switzerland. The American biotech company is currently setting up its first commercial office outside of North America, near the pharmaceutical stronghold of Basel. Up to 30 specialists will be hired there by the end of the year, says a BLICK spokesperson.
Another 30 specialists will be added in 2021, mainly people who already have experience in the areas of approval, medicine, quality, production and trade, a company spokesperson said.
Moderna is considered a promising candidate to soon produce the first effective corona vaccine. That is why Switzerland has signed its first agreement with him for a possible corona vaccine. The purchase agreement includes the delivery of 4.5 million doses of vaccine.
Dan Staner becomes the head of Switzerland
Now it is also known who is responsible for the presence and activities of Moderna in Switzerland. With Dan Staner (52), the company recruits a pharmaceutical expert. The Swiss citizen has more than 25 years of experience in the global pharmaceutical industry, mainly in Eli Lilly. According to Moderna, Staner has an “excellent track record” within the biopharmaceutical industry.
Staner will establish the Basel headquarters as the center of Moderna’s activities in Europe. “However, we want to keep our organizational structure and physical presence flexible, so our offices in Switzerland will be where our talents can be found,” says Moderna’s spokesperson.
The vaccine could be here soon
The Moderna vaccine against Covid-19 is currently in the final phase of the study before its possible approval. In an interview with the magazine “Bilanz”, Stéphane Bancel (48), executive director of Moderna, says today: “Our vaccine should be ready by the end of January 2021 at the latest”. This is an advertisement!
Even in the last phase of the study, setbacks and problems with disease occurred over and over again in the test subjects. Astra Zeneca recently reported on one such setback. One subject became ill and vaccine studies were discontinued.
Astra Zeneca has high expectations. The British drugmaker is one of those who, like Moderna, are at the forefront of the race for a corona vaccine. The EU, the US and Britain have already insured millions of ‘AZD1222’ cans.
Although the so-called agent against the coronavirus has not yet been approved anywhere. Switzerland is also holding talks with Astra Zeneca. A second vaccine deal after Moderna’s has yet to close.
